A rheumatoid arthritis drug from Incyte (INCY), once expected to result in blockbuster sales, has won approval for only a narrow group of patients and will carry a label warning of serious safety risks that are likely to limit its market potential.

The pill, to be marketed as Olumiant, won Food and Drug Administration approval Friday, a minor consolation for Incyte and partner Eli Lilly (LLY) as the companies adjust their revenue expectations for the drug.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy